First Trust Nasdaq Pharmaceuticals ETF
FTXH
26 hedge funds and large institutions have $18.3M invested in First Trust Nasdaq Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
30% more funds holding
Funds holding: 20 → 26 (+6)
6% less capital invested
Capital invested by funds: $19.4M → $18.3M (-$1.13M)
30.94% less ownership
Funds ownership: 81.66% → 50.72% (-31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$4.27M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$3.23M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.1M |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$819K |
| 5 |
KNW
Kesler Norman & Wride
Ogden,
Utah
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$6.33M |
| 2 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$4.21M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$652K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$507K |
| 5 |
Jane Street
New York
|
-$397K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DADC
26
D.A. Davidson & Co
Great Falls,
Montana
| – | -$6.33M | -239,586 | Closed |
|
|
AWM
27
AE Wealth Management
Topeka,
Kansas
| – | -$4.21M | -159,408 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$652K | -24,675 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$507K | -19,181 | Closed |
|
|
30
Jane Street
New York
| – | -$397K | -15,010 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$2K | -88 | Closed |
|
FTXH Hedge Fund Activity: Q3 2022 in Review
26 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2022, worth a combined $18.3M — down 5.8% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FTXH positions and 6 closed out — a net gain of 6 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Truist Financial, adding an estimated $4.27M. The largest seller was D.A. Davidson & Co, exiting entirely with an estimated $6.33M sold.
- 26 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2022, up from 20 in Q2 2022.
- Funds reported $18.3M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2022, down 5.8% quarter-over-quarter.
- 12 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2022 and 6 closed out, a net change of +6 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2022 was Truist Financial, an estimated $4.27M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2022 was D.A. Davidson & Co, an estimated $6.33M sold.
Based on aggregated 13F filings for Q3 2022.